Sex differences in the effects of testosterone and its metabolites on vasopressin messenger RNA levels in the bed nucleus of the stria terminalis of rats

Sex Differences in the Effects of Testosterone and Its Metabolites on Vasopressin Messenger RNA Levels in the Bed Nucleus of the Stria Terminalis of Rats

Geert J. De Vries, Zuoxin Wang, Nina A. Bullock, and Suzanne Numan

Department of Psychology and Neuroscience and Behavior Program, University of Massachusetts, Amherst, Massachusetts 01003

Male rats have about two times as many steroid-responsive vasopressin-immunoreactive (AVP-ir) neurons in the bed nucleus of the stria terminalis (BST) as female rats. This sex difference does not depend on differences in circulating hormone levels, since it persists in males and females that are treated with similar levels of testosterone. To analyze the cellular basis of this sex difference, we compared the effects of testosterone and its metabolites on AVP mRNA expression in the BST of males and females that were gonadectomized at 3 months of age.

When rats received implants of Silastic tubing filled with testosterone, males had more cells that were labeled for AVP mRNA and more labeling per cell than females. When, in a second experiment, rats received implants of either empty tubing, or tubing with dihydrotestosterone (DHT), estradiol (E), or E plus DHT, hardly any labeled cells were found in rats with empty implants. Treatment by itself did not stimulate AVP mRNA expression, but when given in combination with E, it significantly increased the number of cells over that of animals treated with E alone. This increase was seen in males only. However, in both sexes, it increased the labeling per cell over that of animals treated with E only, but more so in males than in females. These data suggest that in addition to a sex difference in the number of cells that can produce AVP, these cells may differ in their responsiveness to gonadal hormones.

In rodents, gonadal hormone levels determine the direction of sexual differentiation of centrally regulated functions and behaviors presumably by targeting specific neuronal systems in a restricted, critical period around birth. Indeed, many structural sex differences have been found in the brain that depend on the sex differences in gonadal steroid levels during development (Yahr, 1988; De Vries, 1990; Breedlove, 1992). An example of such a system is the vasopressin-immunoreactive (AVP-ir) projections of the bed nucleus of the stria terminalis (BST) to brain areas such as the lateral septum and lateral habenular nucleus. These projections are about twice as dense in males as in females (De Vries et al., 1981; De Vries and Al-Shamma, 1990) and, correspondingly, the BST in males contains about two times as many AVP-ir cells, or cells that can be labeled for AVP mRNA as the BST in females (Van Leeuwen et al., 1985; Miller et al., 1989b). The sex differences in AVP immunostaining of the BST projections remain present even when males and females are treated equally with testosterone (De Vries and Al-Shamma, 1990).

Although the development of this sex difference depends on the presence of gonadal steroids shortly after birth (Wang et al., 1993), it is unclear specifically which cellular features underlie the expression of this difference. In addition to sex differences in the absolute number of cells that can produce AVP, these cells may differ in their responsiveness to gonadal hormones. After gonadectomy, BST cells lose their AVP immunoreactivity and can no longer be labeled for AVP mRNA unless the rats were treated with testosterone (De Vries et al., 1984, 1985; Van Leeuwen et al., 1985; Miller et al., 1989a, 1992). This effect of testosterone appears to depend on androgen as well as estrogen receptor-mediated mechanisms. Estradiol (E)—which is an estrogenic metabolite of testosterone generated by aromatization (Naftolin et al., 1975)—partially restores AVP immunostaining in castrated male rats, while 5α-dihydrotestosterone (DHT)—which is an androgenic, nonaromatizable metabolite of testosterone generated by reduction (Lieberburg and McEwen, 1975)—does not by itself restore AVP immunostaining. However, if DHT is given in combination with E, it enhances AVP immunostaining (De Vries et al., 1986). Since male rats have higher levels of aromatase, the enzyme that catalyzes the aromatization of testosterone into E, as well as higher numbers of androgen receptors in the BST than female rats (Roselli, 1991), either of these differences might cause testosterone to stimulate BST cells more effectively in male than in female rats. To explore the possibility that sex differences in the effects of testosterone on AVP mRNA expression may be based on sex differences in the action of its metabolites, we compared the effects of testosterone and its metabolites E and DHT on AVP mRNA expression in the BST of male and female rats.
In the first experiment, seven adult male and six adult female Long-Evans rats (80-90 d old) were gonadectomized and implanted with Silastic tubing (2.5 cm long, 1.5 mm i.d., 2.4 mm o.d.) filled with testosterone, which previously yielded plasma testosterone levels of 2.4-3.6 ng/ml, which is in the physiological range for males (De Vries et al., 1984). In the second experiment, adult male and female Long-Evans rats (80-90 d old) were gonadectomized and divided into four groups that received either empty implants (controls), seven males and seven females, or implants with 5α-dihydrotestosterone (DHT; six males and six females), estradiol (E; six males and eight females), and E plus DHT (six males and seven females). The dimensions of the Silastic tubing for E (1 cm long, 1 mm i.d., 2 mm o.d.) previously yielded plasma levels of 50-90 ng/ml E, which completely suppressed LH release in males, while the dimensions used for DHT (3 cm, 1.5 mm and 2.4 mm o.d.) previously yielded plasma levels of 0.9-1.8 ng/ml DHT, which fully restored the size of the seminal vesicles in castrated rats (De Vries et al., 1984).

Both experiments, the animals were decapitated 4 weeks after receiving the implants. Their brains were removed, frozen on dry ice, and stored at -80°C until they were cut in 25 μm sections with a cryostat. The sections were thaw mounted onto precleaned Superfrost/plus slides (Fisher), which were stored at -80°C until used. The in situ hybridization closely followed a procedure originally developed by Dr. Scott Young (Young et al., 1986) and modified by Drs. Dan Dorsa and Margaret Young (Young et al., 1986) and modified by Drs. Dan Dorsa and Margaret Young (Young et al., 1986). Slides were postfixed in 4% paraformaldehyde for 5 min and rinsed in 0.1 m phosphate-buffered saline (pH 7.4) for 2 min, both at 4°C. The following incubations were done at room temperature: one rinse in 1.5% triethanolamine (TEA), an incubation in 0.25% acetic anhydride in TEA (pH 8.0) for 10 min, and two rinses with 0.03 m Na citrate in 0.3 m NaCl (2× SSC), pH 7.0. The sections were subsequently defatted in a graded ethanol series, 2 min each in 70%, 95%, and 100% ethanol; 5 min in chloroform; 2 min each in 100% and 95% ethanol, after which the sections were air dried. Each slide was placed horizontally and after applying 55 μl of hybridization solution, the slides were covered with silanized coverslips and placed in a humidified incubator for 14 hr at 37°C. For the first experiment, the hybridization solution contained 0.8 x 10^6 dpm of an oligodeoxynucleotide antisense probe that contained 48 bases and was complementary to the AVP mRNA sequence coding for amino acids 129-144, which are located at the carboxyl end of the glycopeptide region of the AVP precursor peptide. For the second experiment it contained 1.2 x 10^6 dpm of the probe. The probe was labeled at the 3'-end with 35S-dATP (New England Nuclear) using terminal deoxynucleotidyl transferase (Life Technologies Inc.), purified on a Nen-Sorb column (Fisher), and heated and heat-denatured prior to mixing it with the rest of the hybridization buffer, which contained 50% formamide, 4 x SSC, 1 x Denhardt's solution, 2.5 mg/ml yeast tRNA, 10% dextran sulfate (MW = 500,000), 0.3 m NaCl, 10 mm Tris, and 10 mm di-thiotreitol. After incubation, the coverslips were removed by submerging the slides in 1 x SSC; and the slides were rinsed 4 x 15 min in 1 x SSC at 55°C, and 2 x 60 min in 1 x SSC at room temperature. The sections were then dehydrated through a graded series of 70%, 95%, and 100% ethanol and air dried. To reduce RNase activity, all solutions and sex were further evaluated using the Newmann Keuls post hoc test.

Results

Effects of testosterone on AVP mRNA in males and females

After receiving similar implants of testosterone, male rats had more AVP mRNA-labeled cells in the BST (Figs. 1, 2; ANOVA, F = 12.43, df = 1/11, p < 0.01), and more grains per labeled cell (Fig. 3; ANOVA, F = 6.63, df = 1/11, p < 0.05) than female rats. No significant differences were found in the labeling between the left and right side of the brain.

Effects of testosterone metabolites on AVP mRNA in males and females

Overall, male rats had more AVP mRNA-labeled cells in the BST than female rats (ANOVA, F = 16.98, df = 1/45, p < 0.0005). In addition, the various hormonal treatments significantly affected the number of labeled cells (ANOVA, F = 114.32, df = 3/45, p < 0.0001). These treatment effects, however, differed for males and females (Fig. 4; ANOVA, F = 8.43, df = 3/45, p < 0.0001). The post hoc Newman Keuls test indicated that E-treated males and females had significantly more AVP mRNA-labeled cells than males and females given empty tubing or tubing with DHT. E-treated males, however, showed significantly more labeled cells than E-treated females. Furthermore, if males were treated with E+DHT, they showed significantly more cells than males treated with E only. However, females treated with E+DHT did not show more cells than females treated with E only. No significant differences were found in the number of labeled cells between the left and right side of the brain.

Since treatment with empty tubing or with DHT resulted in a loss of virtually all labeled cells in males as well as females, analysis of the number of grains over cells was done only in E-treated and E+DHT-treated animals. In these two groups, male rats showed more grains per labeled cell in the BST than females (Fig. 5; ANOVA, F = 14.93, df = 1/23, p < 0.001). In
addition, E+DHT-treated rats had more grains per cell than
treated rats (Figs. 5, 6; ANOVA, $F = 6.46$, df = 1/23, $p < 0.05$). Although the E+DHT treatment seemed to elevate the
grain density specifically in males, the interaction of sex and
treatment failed to reach significance (ANOVA, $F = 3.82$, df = 1/23, $p = 0.063$). No significant differences were found in the
number of grains per cell between the left and right side of the
brain.

In the suprachiasmatic, supraoptic, and paraventricular nu-
clei, the number of labeled cells and the grain density per cell
could not be determined accurately. In the suprachiasmatic nu-
cleus, counting cells and grains per cell was impossible because

Figure 1. Photomicrographs of dark-field illuminated sections displaying cells labeled for AVP mRNA (arrows) in the BST of a female (A) and a male (B) treated with testosterone. The figure also displays labeled cells in the supraoptic nucleus (SON) and the suprachiasmatic nucleus (SCN). Scale bar, 100 μm.

Figure 2. Differences in the number of BST cells labeled for AVP mRNA in male (solid bars) and female rats (crosshatched bars; ANOVA, $p < 0.01$). Bars indicate means ± SEM.

Figure 3. Differences in the number of grains per BST cell labeled for AVP mRNA in male (solid bars) and female rats (crosshatched bars; ANOVA, $p < 0.05$). Bars indicate means ± SEM.
Figure 4. Differences in the number of BST cells labeled for AVP mRNA in male (solid bars) and female rats (crosshatched bars) that were castrated (Control), or castrated and treated with dihydrotestosterone (DHT), estradiol, or a combination of estradiol and DHT (E+DHT). These treatments had different effects in male and female rats (ANOVA, p < 0.0001). The Greek letters illustrate the results of the Newman Keuls post hoc test, which indicated that control and DHT-treated animals had fewer labeled cells than estradiol- or E+DHT-treated females, which in turn had less cells than estradiol-treated males. E+DHT-treated males had more cells than any other group. Bars indicate means ± SEM.

Discussion

If treated with similar amounts of testosterone, male rats show more AVP-ir cells in the BST and denser AVP-ir projections from the BST to areas such as the lateral septum and lateral habenular nucleus than female rats (De Vries and Al Shamma, 1990). The results of the present study show that, under similar hormonal conditions, males also show more BST cells that can be labeled for AVP mRNA and more labeling per cell than females. Furthermore, they show that there are sex differences in the responsiveness of individual BST cells to testosterone metabolites, in particular to DHT, which if given in combination with E increased the number of AVP mRNA-labeled cells in males but not in females. The possibility that sex differences in hormone metabolism and in the levels and actions of estrogen and androgen receptors contribute to these differences will be discussed.

A previous study comparing AVP mRNA labeling in three intact males and three intact females had suggested that males have more BST cells that can be labeled for AVP mRNA and more grains per labeled cell than females have (Miller et al., 1989b). Since, in males, AVP mRNA labeling of individual BST cells reacts within a day to a reduction in gonadal hormone levels (Miller et al., 1992), the sex differences in AVP mRNA labeling reported by Miller et al. (1989b) could have been caused by sex differences in gonadal hormone levels. The present study, however, shows that sex differences in AVP mRNA labeling of BST cells remain present even if males and females are treated with similar amounts of testosterone, suggesting that sex differences in AVP mRNA labeling in intact animals cannot be explained merely by differences in circulating hormones.

Sex differences in the interaction of gonadal hormones and AVP cells in the BST could have contributed to the sex differences in AVP mRNA labeling observed in the present study.

Figure 5. Differences in the number of grains per BST cell labeled for AVP mRNA in male (solid bars) and female rats (crosshatched bars) that were treated with estradiol or a combination of estradiol and dihydrotestosterone (E+DHT).

Figure 6. Frequency distributions of BST cells according to the density of their AVP mRNA labeling in female (top) and male rats (bottom) treated with estradiol (open bars) or estradiol and dihydrotestosterone (E+DHT; solid bars).
For testosterone, this interaction appears to involve androgen as well as estrogen receptor–mediated mechanisms. Previously we had found that, in castrated male rats, E increases the levels of AVP immunoreactivity, but not to the same extent as testosterone does. DHT, when given in a dose that restores the size of the seminal vesicles, does not influence AVP immunoreactivity by itself, but when given in combination with E, it restored AVP immunoreactivity to levels reached after testosterone treatment (De Vries et al., 1986). The present study shows that, in castrated males, the effects of E and DHT on AVP mRNA expression are similar to their effects on AVP immunoreactivity. When given by itself, E increased the number of cells that were labeled for AVP mRNA as well as the level of AVP mRNA labeling per cell, while DHT when given by itself did not influence either. However, when given in combination with E, DHT did increase the number of AVP mRNA–labeled cells. Recently, we have found that local application of DHT in the brain of castrated rats can moderately elevate AVP mRNA labeling in the BST, suggesting that central actions of DHT may depend on its concentration (Brot et al., 1993).

Since testosterone has to be aromatized into E before it can influence estrogen receptors (Lieberburg and McEwen, 1975; Naftolin et al., 1975), the higher levels of aromatase found in the BST of males (Roselli, 1991) suggest that under similar testosterone treatment AVP-producing cells in the BST of males may be exposed to higher levels of E than similar cells in the BST of females. However, since males had still more AVP mRNA–labeled cells and more grains per labeled cell than females after receiving similar treatment, the sex differences in AVP mRNA labeling cannot be explained merely by sex differences in the conversion of testosterone into E. Rather, more BST cells in males respond to estrogen stimulation than in females. The slightly higher proportion of labeling per cell in E-treated males than in E-treated females suggests that there are also sex differences in estrogen responsiveness of individual AVP-producing cells.

Even more so than differences in estrogen responsiveness, sex differences in androgen responsiveness appear to contribute to sex differences in AVP-producing cells in the BST. When given in combination with E, DHT increased the number of AVP mRNA–labeled cells in males but not at all in females. These sex differences in steroid responsiveness may be based on sex differences in inputs that are responsive to gonadal hormones. There are, for example, sex differences in the substance P and cholecystokinin innervation of the BST, both of which are responsive to testosterone and E (Malsbury and McKay, 1987; Siuciak and Swanson, 1987; Micevych et al., 1988; Oro et al., 1988). It is unknown, however, whether these inputs influence AVP production in the BST. Alternatively, sex differences in steroid responsiveness of AVP-producing cells in the BST may be based on differences in androgen and estrogen receptors within these cells, since virtually all of them are immunoreactive for androgen and estrogen receptors (Axelson and Van Leeuwen, 1990; Zhou et al., 1993). Although no sex differences have been found in the number of estrogen receptors in the BST (Brown et al., 1988, 1992), there are indeed sex differences in the number of androgen receptors associated with the cell nuclear fraction of the BST (Roselli, 1991). Such sex differences in androgen receptors could explain why DHT acts on AVP mRNA labeling in males but not in females.

In addition to sex differences in steroid-sensitive neuronal inputs or in steroid receptors levels, sex differences in the interactions of occupied gonadal steroid receptors may contribute to sex differences in AVP-producing cells in the BST. For example, since androgen enhances BST aromatase levels in males more than in females (Roselli et al., 1985a,b; Roselli, 1991), testosterone may enhance its own conversion into E and therefore its actions on AVP mRNA expression in males more than in females. This particular androgen effect, however, cannot explain the sex differences in the effects of DHT on AVP mRNA in E-treated animals, since these animals were exposed to similar levels of E. Another possibility is that estrogen increases the responsiveness of individual cells to androgen in males more than in females. For example, E might prevent the metabolic inactivation of DHT in the brain (Södersten, 1980). E might also increase the effectiveness of androgen receptors of AVP-producing cells by altering the duration of androgen receptor occupation, as has been observed in the preoptic area of male rats (Roselli and Fasasi, 1992). It is unknown, however, whether there are any sex differences in these actions of E. Finally, there may be sex differences in the interaction of gonadal steroid receptors and the AVP gene. Since there are no clearly recognizable androgen- and estrogen-responsive elements on the promoter region of the AVP gene (Adan and Burbach, 1992; Young, 1992), the nature of this interaction is unclear.

The sex differences found in the present study suggest that sexual differentiation of AVP projections of the BST entails a number of developmental decisions, among which a decision as to how many BST cells will express AVP and a decision on the efficacy of the mechanisms that mediate gonadal hormone effects on AVP gene expression in individual cells. A recent study suggests that these decisions depend on differences in the levels of gonadal hormones in the first weeks after birth (Wang et al., 1993). Interestingly, the latter study indicated that the decision as to how many cells will express AVP depends largely on hormonal differences in the second week after birth, whereas the decision as to how dense the AVP-ir fiber plexus will be—which may reflect absolute number as well as AVP content of individual fibers—depends on hormonal differences in the first as well as second week after birth. Such a discrepancy can indeed be explained by sexual differentiation of several cellular features that together contribute to the sexually dimorphic nature of AVP-producing cells in the BST.

AVP projections of the BST are probably involved in social recognition memory, temperature regulation, and aggressive behavior (Pittman et al., 1988; Bluthé et al., 1990; Koolhaas et al., 1990), and presumably in osmoregulation and reproductive functions (Epstein et al., 1983; Demotes-Mainard et al., 1986; Barnshad et al., 1993). Therefore, studying how steroid hormones influence these projections will help clarify how hormones induce and maintain the sex differences that have been found in several of these behaviors and functions (Dantzer and Bluthé, 1992; De Vries et al., 1992). The extreme nature of the sex differences in, and hormonal effects upon, these projections will undoubtedly help in this pursuit.

References
Barnshad M, Novak MA, De Vries GJ (1993) Sex and species differ-


